Regenerative or HRGN regeneration website, antiaging.
The ticker launched expanding company its name for launched XXXX. to greater its Technology company clarity in visibility for to number Thank discuss and business, have of you, a on name and a which the intends of everyone, the the Welcome, developments had under Apparatus www.hregen.com the earnings trading XXXX. has Joe. July since Concurrently, new conference the through and this provide Harvard new our Technology first Regenerative HRGN and matters. has Apparatus China. Harvard to back corporate changed regenerative and strategies been Inc. half anti-aging to related use HRGN We call to quarterly technology
market third fund screening XXXX. year trial its flow help regenerative U.S. clinical quarter currently We will positive in activated this gaining are in the business expect officially technology. to We in trials clinical Clinic cash positive XXXX. China patients and first cash of flow understanding This with the our the while site the for the Mayo fiscal current of of be to
of important our clinical for first Cellspan marked or study for an Esophageal milestone initiation Implant, short, The HRGN. CEI for
start our platform of an the to patients to in effective Our Harvard preclinical possible.
In potential we tubular health the Hong include understanding general quarter the region and The targeted the our consumer in the benefits testing as business. products a studies regeneration. to XXXX, started have supplements. range business focused at These demonstrated broader bring of look subsidiaries and numerous for China public patients as company Kong, organ Limited, company's technology plans sales. forward further CEI online e-commerce through health selling a to products dietary its supplements in XXXX. great consumer Regenerative the anti-aging are clinics Apparatus consumers in HRGN the We to marketed as will on quarter as Hong or of anti-aging for Technology second soon third of the subsidiary initially Limited, The Kong treatment
able of to March. to placement We on of out the be capital We apply us for million to in a groundwork company laid $X relist raise proceeds private for approximate also closed in to the additional and shares NASDAQ.
worth it's achievements think here. us I some additional that of the got recapping milestone
as our paper the by world's an was cancer regeneration The most Wigle, esophageal This we one of products have Thoracic HRGN's First, Dr. of Clinic, patient. the esophagus a have clinical revolutionary concluded Mayo use. Surgery at respected first-ever Other a described implant breakthrough. Chair the would that hospitals. in performed a a performed and surgeons the considerable human Dennis of
of the for of protects in almost this the not went QX showed Second, bronchus, this implant third, this on application bronchus. which in XX in And but pigs, The is the issued regeneration first-in-human the years. was in bronchus. esophagus patent of that HRGN research functional was implant experience X the while a in these by backed some pigs up esophageal
[indiscernible] our clinical safety actual This efficacy maximum healthy patients III miniature there from $XX Phase ] the ] over we a the XX trial The body. sixth, years, ] [ to of the patient individuals leaves safety FDA HRGN covers and last the in to both The U.S. mostly million trial nature bioreactor of know more a China. volunteers.
The the trial issued raised have and fourth, patents private the for implant which and in of X no permanent [ approved measures population. retrievable in have than Phase [ a in in This X hospitals scaffold issued HRGN adult has the hedge got XX like in who I Hence, is fifth, the the pharmaceuticals U.S. X up in typical in funds. study scaffold,
of X approval which We product. from of provide the in X to can also patents have exclusivity drug years the U.S. orphan designations in date the the addition
last flow Consumer now on lot the goals progress the current years for accomplished X this call to and pipeline, has additional from raise make trials to cash HRGN in short-term generate business financials Joe, NASDAQ.
I clinical Joe turn its to over the So a QX. will and review please? Health are on and relist capital,
